Effect of fezolinetant on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history: pooled data from two randomized phase 3 studies

被引：0
作者：
Santoro, Nanette [1 ]
Neal-Perry, Genevieve [2 ]
Stute, Petra [3 ]
Blogg, Martin [4 ]
Mancuso, Shayna [5 ]
Morga, Antonia [4 ]
Ottery, Faith D. [5 ]
Siddiqui, Emad [4 ]
机构：
[1] Univ Colorado, Sch Med, Aurora, CO USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Inselspital Bern, Bern, Switzerland
[4] Astellas Pharma Europe Ltd, Addlestone, Surrey, England
[5] Astellas Pharma Global Dev Inc, Northbrook, IL USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
S-8
引用
收藏
页码：1259 / 1259
页数：1
相关论文
共 50 条
  • [21] Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
    Simpson, Eric L.
    Pink, Andrew E.
    Blauvelt, Andrew
    Gooderham, Melinda
    Armstrong, April W.
    Worm, Margitta
    Katoh, Norito
    Peris, Ketty
    Puig, Luis
    Barbarot, Sebastien
    Mark, Thomas
    Steffensen, Louise Abildgaard
    Tindberg, Ann-Marie
    Wollenberg, Andreas
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (06) : 939 - 952
  • [22] Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
    Eric L. Simpson
    Andrew E. Pink
    Andrew Blauvelt
    Melinda Gooderham
    April W. Armstrong
    Margitta Worm
    Norito Katoh
    Ketty Peris
    Luis Puig
    Sébastien Barbarot
    Thomas Mark
    Louise Abildgaard Steffensen
    Ann-Marie Tindberg
    Andreas Wollenberg
    American Journal of Clinical Dermatology, 2023, 24 : 939 - 952
  • [23] Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
    Blauvelt, Andrew
    Papp, Kim A.
    Lebwohl, Mark G.
    Green, Lawrence J.
    Hsu, Sylvia
    Bhatt, Varsha
    Rastogi, Shipra
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (02) : 372 - 374
  • [24] Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials
    Simpson, E. L.
    Rahawi, K.
    Hu, X.
    Chu, A. D.
    Nduaka, C.
    Jazayeri, S.
    Lio, P.
    Lynde, C.
    Schuttelaar, M. L. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1863 - 1870
  • [25] Secukinumab in moderate to severe hidradenitis suppurativa: Analysis of pooled data from the SUNSHINE and SUNRISE phase 3 randomized trials
    Alavi, Afsaneh
    Reguiai, Ziad
    Jemec, Gregor B. E.
    Gottlieb, Alice B.
    Wozniak, Magdalena B.
    Uhlmann, Lorenz
    Fan, Heng
    Llobet-Martinez, Angela
    Ravichandran, Shoba
    Kimball, Alexa B.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 137 - 138
  • [26] Treatment of moderate-to-severe acne with once-daily tazarotene 0.045% lotion in pediatric patients: Pooled analysis of two phase 3 studies
    Eichenfield, L. F.
    Tanghetti, E.
    Guenin, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S82 - S82
  • [27] Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan
    Tanghetti, Emil A.
    Bagel, Jerry
    Yamauchi, Paul S.
    Gold, Linda Stein
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 855 - 861
  • [28] Dupilumab in moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials (SOLO 1 & 2)
    Simpson, E. L.
    Bieber, T.
    Guttman-Yassky, E.
    Beck, L. A.
    Blauvelt, A.
    Cork, M. J.
    Silverberg, J. I.
    Deleuran, M.
    Kataoka, Y.
    Lacour, J. -P.
    Kingo, K.
    Worm, M.
    Poulin, Y.
    Wollenberg, A.
    Soo, Y.
    Graham, N. M. H.
    Pirozzi, G.
    Akinlade, B.
    Staudinger, H.
    Mastey, V.
    Eckert, L.
    Gadkari, A.
    Ardeleanu, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 79 - 79
  • [29] Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52
    Sticherling, M.
    Nikkels, A. F.
    Hamza, A. M.
    Kwong, P.
    Ortmann, C. -E.
    Papanastasiou, P.
    Forrer, P.
    Keefe, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E39 - E40
  • [30] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Peserico, A.
    Fumero, E.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47
12345